NCT03302351View on ClinicalTrials.gov

Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

March 1, 2018

Study Completion Date

April 1, 2018

Conditions
Shivering
Interventions
DRUG

Dexmedetomidine

30 patients will receive intravenous dexmedetomidine 1 mcg/kg.

DRUG

ketamine

31 patients will receive intravenous ketamine 0.4 mg/kg.

DRUG

Dexmetedomidine+Ketamine

33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.

Trial Locations (1)

Unknown

Ghada Mohammmad Aboalfadl, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03302351 - Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia | Biotech Hunter | Biotech Hunter